Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“FDA approves a first-in-class hypertension drug!
The US FDA has recently approved Baxfendy (baxdrostat) by AstraZeneca, the first-ever aldosterone synthase inhibitor for hypertension treatment.
What makes this approval significant is its completely new mechanism of action. Instead of only managing symptoms, the drug directly targets aldosterone production, a hormone linked to persistently high blood pressure and cardiovascular risk.
In Phase III trials, the drug demonstrated clinically meaningful reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications.
This marks one of the most important cardiovascular drug innovations in recent years and highlights how pharma continues to evolve toward more targeted and mechanism-based therapies.
Exciting to see innovation reshaping chronic disease management.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association